RELATIONSHIP OF RISK FACTORS WITH HISTOPATHOLOGICAL TYPES IN CERVICAL CANCER PATIENTS IN DR SOETOMO HOSPITAL

2021 ◽  
Vol 7 (1) ◽  
pp. 56-63
Author(s):  
Anggray Puspasari ◽  
Pungky Mulawardhana ◽  
,Nila Kurniasari
Keyword(s):  
Risk Factors ◽  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Cross Sectional ◽  
Contingency Coefficient ◽  
Relationship Of ◽  
Histopathological Type

Cervical cancer is a process of changing into malignancy in the cervix. Based on studies and previous research, cervical cancer is the third female cancer in terms of incidence (527,600 new cases) and mortality (265,700 deaths) in the world. Cervical cancer has histotopathological types in the form of squamous cell carcinoma, adenocarcinoma, and other types. This study aimed to analyze the relationship of risk factors with histopathological types in cervical cancer patients in Dr. Soetomo Hospital. Method: This analytical descriptive study used a cross sectional research design. The number of samples were 300 patients collected by total sampling. Independent variables were risk factors including age, marital age, parity, smoking, oral contraceptives, and education while dependent variables were histopathological types including squamous cell carcinoma, adenocarcinoma, and other types. Instruments used documentation. Data analysis used chi square, fisher and contingency coefficient tests. Results: There was a relationship of cervical cancer risk factors of age to histopathological type (p= 0.000 and contingency coefficient = 0.170) and no relationship of risk factors to number of parity (p= 0.321 and contingency coefficient = 1000 0.064 ), marriage age (p = 0.720 and contingency cofience = 0.038), smoking (p = 0.711 and contingency cofience = 0.036), oral contraceptive (p = 0.655 and contingency comfience = 0.042), education (p = 0.744 and contingency co-efficiency = 0.089) to histopathological type. Conclusion:  There is a relationship between risk factors and histopathological types in cervical cancer patients at Oncology Polyclinic at Dr Soetomo Hospital of Surabaya.  

Squamous Cell Carcinoma Antigen Isoforms in Serum from Cervical Cancer Patients

Tumor Biology ◽  
2006 ◽  
Vol 27 (3) ◽  
pp. 142-152 ◽  
Author(s):  
Eva Röijer ◽  
Henk W.A. de Bruijn ◽  
Ulrika Dahlén ◽  
Ka ten Hoor ◽  
Maria Lundin ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Squamous Cell Carcinoma Antigen

scholarly journals Prognostic Impact of Histopathology in Patients with Advanced Stage Cervical Carcinoma Treated with Radiotherapy

2019 ◽  
Vol 37 (4) ◽  
pp. 175-180
Author(s):  
Nasrin Hossain ◽  
Rahana Perveen ◽  
Mohammed Sharif Mahmud ◽  
Mohammed Kabirul Hassan
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cervical Carcinoma ◽  
Squamous Cell ◽  
Disease Free Survival ◽  
Advanced Stage ◽  
Free Survival ◽  
Histopathological Type ◽  
Disease Free

Introduction: Cervical cancer is the fourth most common cancer in women worldwidev . Most patients in developing countries including Bangladesh present at advanced stage. Histopathological types of cervical cancer influence the treatment outcome when treated by radiation therapy. Objective: To determine the disease free survival (DFS) in different histopathological types in advanced stage cervical carcinoma treated with radiotherapy. Methods: A prospective cohort study was conducted in Gynaecological oncology outpatient department (GOPD) of National institute of Cancer Research & Hospital (NICRH), Dhaka for one year from September’2016 to July’2017. Advanced stage (IIB-IVB) cervical cancer who completed radiation therapy and histopathological type either squamous cell carcinoma or adenocarcinoma of cervix were included in this study. Results: The median follow-up time was 1.82 years; range was 8 to 24 months. Average disease free survival (DFS) was 1.53years in squamous cell carcinoma (SSC) and 1.51 years in adenocarcinoma (ADC). Local recurrences was higher in adenocarcinoma group (62.5%) than squamous cell carcinoma (30.5%) & the difference was statistically significant (p = 0.001). Loco-regional recurrence and distal recurrence were also higher in ADC than SSC but results were not statistically significant (p=.345, p=.795). In multivariate analysis it was shown that histopathological type and stage of disease were found to be independently significant prognostic factors for DFS, hazard ratio were 1.766 (p=.018) and 2.173 (p=.006). Conclusion: Adenocarcinoma was a poor prognostic factor for patients with locally advanced cervical carcinoma. Advanced stage of disease was also significant predictor for disease free survival. J Bangladesh Coll Phys Surg 2019; 37(4): 175-180

scholarly journals Preoperative SCC-Ag as a predictive marker for the use of adjuvant chemotherapy in cervical squamous cell carcinoma with intermediate-risk factors

2020 ◽  
Author(s):  
Hong-tao Guo ◽  
Xue-han Bi ◽  
Ting Lei ◽  
Xiao Lv ◽  
Guang Yao ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Adjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Distant Metastasis ◽  
Adjuvant Radiotherapy ◽  
Disease Free Survival ◽  
Free Survival

Abstract Background For cervical cancer patients whose tumors display a combination of intermediate risk factors, postoperative radiation with or without adjuvant chemotherapy is suggested for them. However, who should be administered with adjuvant chemotherapy is unknown. The current study was designed to explore the clinical value of squamous cell carcinoma antigen in guiding the use of adjuvant chemotherapy in cervical cancer patients.Methods A retrospective study of 301 cervical cancer patients treated by surgery and adjuvant treatment from Mar. 2005 to Mar. 2015 was performed. All patients were divided into two groups according to receiving adjuvant chemotherapy or not. Overall survival (OS), disease-free survival (DFS) were compare between patients who did and did not receive adjuvant radiotherapy. Multivariate analysis was employed to detect clinical factors associated with disease-free survival, local recurrence-free survival and distant metastasis-free survival.Results For patients with high pre-treatment squamous cell carcinoma level, DFS and OS in adjuvant chemo-radiotherapy group were higher than that in adjuvant radiotherapy group. Besides, the rates of distant metastasis were found lower in patients who did receive adjuvant chemotherapy than those who did not. For patients with upper low pre-treatment squamous cell carcinoma level, the 5-year OS and DFS were similar between groups of adjuvant chemo-radiotherapy and adjuvant radiotherapy. Multivariable analysis indicated adjuvant chemotherapy was independent predictors of DFS and distant metastasis-free survival in patients with high squamous cell carcinoma level.Conclusion Squamous cell carcinoma can serve as an indication for the administration of adjuvant chemotherapy in cervical cancer patients.

Molecular detection of squamous cell carcinoma antigen transcripts in peripheral blood of cancer patients

2006 ◽  
Vol 44 (5) ◽  
Author(s):  
Nur Buyru ◽  
Hatice Tigli ◽  
Derya Duranyildiz ◽  
Nejat Dalay
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Cancer Detection ◽  
Squamous Cell ◽  
Peripheral Blood ◽  
Serum Marker ◽  
Diagnostic Tools ◽  
Squamous Cell Carcinoma Antigen

AbstractThe squamous cell carcinoma antigen (SCC-Ag) has been widely applied as a serum marker in different kinds of cancer and was reported as a target gene for the detection of tumor cells in peripheral blood in cervical cancer. Nucleic acids released into the circulation are non-invasive diagnostic tools for cancer detection. The objective of this study was to determine the utility of SCC-Ag mRNA as a cancer detection marker in blood of cancer patients. For this purpose, 77 blood samples from five gastric cancer, 23 laryngeal cancer, 31 lung cancer, nine esophageal, and nine cervical cancer patients were analyzed. The

Clinical Value of Routine Serum Squamous Cell Carcinoma Antigen in Follow-Up of Patients With Early-Stage Cervical Cancer

2001 ◽  
Vol 19 (19) ◽  
pp. 3960-3966 ◽  
Author(s):  
Martha D. Esajas ◽  
Jitze M. Duk ◽  
Henk W.A. de Bruijn ◽  
Jan G. Aalders ◽  
Pax H.B. Willemse ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Early Stage ◽  
Elevated Serum ◽  
Squamous Cell Carcinoma Antigen ◽  
Early Stage Cervical Cancer

PURPOSE: To investigate the contribution to recurrence detection and survival of serum squamous cell carcinoma antigen (SCC-ag) analysis in the follow-up of early-stage cervical cancer patients. PATIENTS AND METHODS: Follow-up data were evaluated in patients with early-stage squamous cell cervical cancer treated by radical hysterectomy and pelvic lymphadenectomy with or without radiotherapy. Routine serum SCC-ag determination was performed at each follow-up visit. RESULTS: Recurrent disease occurred in 35 (16%) of 225 patients and was preceded or accompanied by serum SCC-ag elevation 26 times (sensitivity, 74%). In five (14%) of these 35 patients, elevated serum SCC-ag was the first measured clinical indicator. Desite salvage therapy, all five patients died of disease. In the other 31 patients (21 with serum SCC-ag elevation), either symptoms and/or positive signs led to recurrence detection. Median survival time after recurrence was worse (9 months; range, 2 to 112+) for patients with an elevated serum SCC-ag value at recurrence in comparison with patients with normal serum SCC-ag values (20 months; range, 4 to 96; P < .01). In 23 of the 190 patients without recurrences, serum SCC-ag values became falsely elevated. In 16 of these 23 patients, the repeat sample after 6 weeks showed a normal SCC-ag, and in seven patients benign (especially skin) disorders were found. CONCLUSION: Serum SCC-ag analysis results in earlier recurrence detection in a small proportion (14%) of patients but did not contribute to better survival. As long as treatment possibilities for recurrent cervical cancer patients are not improved, serum SCC-ag analysis should not be carried out in routine follow-up.

Sign in / Sign up

Export Citation Format

Share Document